We can’t show the full text here under this license. Use the link below to read it at the source.
Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria
Jan 18, 2021The Cochrane database of systematic reviews
Atovaquone-proguanil for treating simple cases of malaria caused by Plasmodium falciparum
AI simplified
Abstract
Seventeen randomized controlled trials involving 4763 participants provided data on the efficacy and safety of atovaquone-proguanil for treating uncomplicated malaria.
- Atovaquone-proguanil is associated with treatment failure rates between 5% and 10% for uncomplicated Plasmodium falciparum malaria.
- Comparisons showed that atovaquone-proguanil had higher PCR-adjusted treatment failures than artesunate-amodiaquine (9.4% vs. 2.9%).
- Similar PCR-adjusted treatment failures were observed between atovaquone-proguanil and artesunate-mefloquine (2.7% vs. 2.4%).
- The combination of atovaquone-proguanil with artesunate resulted in fewer treatment failures compared to atovaquone-proguanil alone at both day 28 and day 42.
- No specific adverse event was strongly associated with atovaquone-proguanil, though some differences in adverse events were noted.
AI simplified
BACKGROUND: The World Health Organization (WHO) in 2015 stated atovaquone-proguanil can be used in travellers, and is an option in malaria-endemic areas in combination with artesunate, as an alternative treatment where first-line artemisinin-based combination therapy (ACT) is not available or effective. This review is an update of a Cochrane Review undertaken in 2005.
OBJECTIVES: To assess the efficacy and safety of atovaquone-proguanil (alone and in combination with artemisinin drugs) versus other antimalarial drugs for treating uncomplicated Plasmodium falciparum malaria in adults and children.
SEARCH METHODS: The date of the last trial search was 30 January 2020. Search locations for published trials included the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, and LILACS. To include recently published and unpublished trials, we also searched ClinicalTrials.gov, the metaRegister of Controlled Trials and the WHO International Clinical Trials Registry Platform Search Portal.
SELECTION CRITERIA: Randomized controlled trials (RCTs) reporting efficacy and safety data for atovaquone-proguanil or atovaquone-proguanil with a partner drug compared with at least one other antimalarial drug for treating uncomplicated Plasmodium falciparum infection.
DATA COLLECTION AND ANALYSIS: For this update, two review authors re-extracted data and assessed certainty of evidence. We meta-analyzed data to calculate risk ratios (RRs) with 95% confidence intervals (CI) for treatment failures between comparisons, and for safety outcomes between and across comparisons. Outcome measures include unadjusted treatment failures and polymerase chain reaction (PCR)-adjusted treatment failures. PCR adjustment differentiates new infection from recrudescent infection.
MAIN RESULTS: Seventeen RCTs met our inclusion criteria providing 4763 adults and children from Africa, South-America, and South-East Asia. Eight trials reported PCR-adjusted data to distinguish between new and recrudescent infection during the follow-up period. In this abstract, we report only the comparisons against the three WHO-recommended antimalarials which were included within these trials. There were two comparisons with artemether-lumefantrine, one trial from 2008 in Ethiopia with 60 participants had two failures with atovaquone-proguanil compared to none with artemether-lumefantrine (PCR-adjusted treatment failures at day 28). A second trial from 2012 in Colombia with 208 participants had one failure in each arm (PCR-adjusted treatment failures at day 42). There was only one comparison with artesunate-amodiaquine from a 2014 trial conducted in Cameroon. There were six failures with atovaquone-proguanil at day 28 and two with artesunate-amodiaquine (PCR-adjusted treatment failures at day 28: 9.4% with atovaquone-proguanil compared to 2.9% with artesunate-amodiaquine; RR 3.19, 95% CI 0.67 to 15.22; 1 RCT, 132 participants; low-certainty evidence), although there was a similar number of PCR-unadjusted treatment failures (9 (14.1%) with atovaquone-proguanil and 8 (11.8%) with artesunate-amodiaquine; RR 1.20, 95% CI 0.49 to 2.91; 1 RCT, 132 participants; low-certainty evidence). There were two comparisons with artesunate-mefloquine from a 2012 trial in Colombia and a 2002 trial in Thailand where there are high levels of multi-resistant malaria. There were similar numbers of PCR-adjusted treatment failures between groups at day 42 (2.7% with atovaquone-proguanil compared to 2.4% with artesunate-mefloquine; RR 1.15, 95% CI 0.57 to 2.34; 2 RCTs, 1168 participants; high-certainty evidence). There were also similar PCR-unadjusted treatment failures between groups (5.3% with atovaquone-proguanil compared to 6.6% with artesunate-mefloquine; RR 0.8, 95% CI 0.5 to 1.3; 1 RCT, 1063 participants; low-certainty evidence). When atovaquone-proguanil was combined with artesunate, there were fewer treatment failures with and without PCR-adjustment at day 28 (PCR-adjusted treatment failures at day 28: 2.16% with atovaquone-proguanil compared to no failures with artesunate-atovaquone-proguanil; RR 5.14, 95% CI 0.61 to 43.52; 2 RCTs, 375 participants, low-certainty evidence) and day 42 (PCR-adjusted treatment failures at day 42: 3.82% with atovaquone-proguanil compared to 2.05% with artesunate-atovaquone-proguanil (RR 1.84, 95% CI 0.95 to 3.56; 2 RCTs, 1258 participants, moderate-certainty evidence). In the 2002 trial in Thailand, there were fewer treatment failures in the artesunate-atovaquone-proguanil group compared to the atovaquone-proguanil group at day 42 with PCR-adjustment. Whilst there were some small differences in which adverse events were more frequent in the atovaquone-proguanil groups compared to comparator drugs, there were no recurrent associations to suggest that atovaquone-proguanil is strongly associated with any specific adverse event.
AUTHORS' CONCLUSIONS: Atovaquone-proguanil was effective against uncomplicated P falciparum malaria, although in some instances treatment failure rates were between 5% and 10%. The addition of artesunate to atovaquone-proguanil may reduce treatment failure rates. Artesunate-atovaquone-proguanil and the development of parasite resistance may represent an area for further research.
Related papers
Jan '19
Pyronaridine-artesunate treatment for simple malaria caused by Plasmodium falciparum
cited by 6 papers
systematic review
Jun '22
Pyronaridine-artesunate treatment for uncomplicated malaria caused by Plasmodium falciparum
cited by 12 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 21 papers
systematic review
Feb '11
Azithromycin for treating simple malaria infections
cited by 24 papers
systematic review
Jan '14
Dihydroartemisinin-piperaquine treatment for simple malaria caused by Plasmodium falciparum
cited by 25 papers
systematic review
Oct '17
Using Mefloquine to Prevent Malaria When Traveling to Risk Areas
cited by 22 papers
systematic review
Mar '14
Using Artesunate and Pyronaridine to Treat Simple Malaria Caused by Plasmodium falciparum
cited by 14 papers
systematic review
Jul '09
Artemisinin-based combination treatment for simple malaria
cited by 98 papers
systematic review
Oct '05
Using atovaquone-proguanil to treat simple malaria
cited by 16 papers
systematic review
Dec '20
Child-friendly artemisinin-based combination treatments for uncomplicated malaria in children
cited by 4 papers
systematic review